Triomics Secures $22 Million to Revolutionize Oncology Data Management Across Cancer Centers
Triomics, an innovative company specializing in oncology AI, has recently completed a Series B funding round, raising an impressive $22 million. The investment was spearheaded by Battery Ventures, with notable contributions from existing investors such as Nexus Venture Partners, Lightspeed, and Y Combinator. This funding has now brought Triomics' total capital raised to over $36 million since its inception in 2021.
The primary objective of this funding is to enhance the adoption of Triomics’ advanced AI platform within health systems nationwide, particularly among leading cancer centers. The company aims to deepen its partnerships within the life sciences sector and expand its teams focused on AI and engineering. The raised capital will significantly accelerate the development of Triomics' AI agents dedicated to improving clinical care and advancing research efforts.
Triomics has formed alliances with several prestigious cancer centers, including the likes of Memorial Sloan Kettering Cancer Center, MD Anderson, and Mount Sinai Tisch Cancer Center. Moreover, the company is collaborating with some of the largest community oncology practices in the United States, for instance, Texas Oncology. Through these partnerships, Triomics intends to tackle the pressing information burden that oncologists face, a challenge that existing systems struggle to manage.
"Oncology is experiencing an overwhelming amount of information that traditional systems were never equipped to handle, hindering the potential for better patient outcomes," explains Sarim Khan, Triomics’ co-founder and CEO. He stresses that clinicians, research coordinators, and medical assistants often grapple with a massive volume of records that have become too complex for manual processing. With Triomics, the goal is to transform this complexity into actionable intelligence embedded within the workflow specifically tailored for oncology.
Beyond simple data handling, Triomics has designed its platform to assist life sciences organizations with pivotal clinical-trial operations. The unique integration of deep provider workflows across cancer centers, coupled with specialized oncology AI infrastructure, aims to construct a robust foundation for future care and research applications.
The challenge faced in cancer care today is not the availability of information but the inefficient utilization of existing data. Patient histories often consist of extensive narratives, comprehensive clinical notes, and various reports and guidelines. The outcome is a labor-intensive process to make this information actionable. "To navigate through thousands of pages of notes and reports intelligently is no small feat," remarks Hrituraj Singh, co-founder and CTO of Triomics.
Triomics was established with the vision of utilizing AI agents to sift through longitudinal patient records, converting disorganized data into coherent, structured, and well-explained outputs. The platform then seamlessly integrates these insights into clinical and operational workflows. Unlike generic summarization tools, Triomics ensures that each output is sourced and verifiable, enriching the clinician’s workflow.
The application of the platform enables proactive clinical trial matching and efficient preparation for patient visits. The functionality also includes oncology data abstraction, ultimately benefiting registry and operational requirements. Data from users indicates remarkable outcomes—trial matches have increased by 40%, enrollments by over 30%, while chart review times were reduced by 67%. Furthermore, the platform has undergone peer-reviewed validation in prestigious journals like Nature Digital Medicine and has been showcased at significant conferences, highlighting the escalating demand for reliable AI capabilities in managing comprehensive patient records.
This evolution in oncology data management is already drawing attention. Dr. Lee Schwamm, the chief digital health officer at Yale New Haven Health System, expresses enthusiasm about partnering with Triomics for oncology clinical trial matching. He notes the time-consuming nature of registry abstraction and aims to automate this process to enhance efficiency and compliance with regulations.
Brandon Gleklen, a principal at Battery Ventures and the newest addition to Triomics' board, commends the groundwork laid by the company, remarking, "Triomics has created AI infrastructure that can function effectively with comprehensive patient data. The results at the leading cancer centers demonstrate tangible outcomes, including expedited enrollment processes and decreased chart review efforts. The unified AI infrastructure underlying these operations is rare for a company at this growth stage."
In summary, Triomics is on a transformative path to redefine clinical workflows in oncology through its cutting-edge AI platform. As they expand their funding and partnerships, the company's mission remains clear: to improve care processes and outcomes for cancer patients while pioneering the next generation of healthcare intelligence in oncology.
The primary objective of this funding is to enhance the adoption of Triomics’ advanced AI platform within health systems nationwide, particularly among leading cancer centers. The company aims to deepen its partnerships within the life sciences sector and expand its teams focused on AI and engineering. The raised capital will significantly accelerate the development of Triomics' AI agents dedicated to improving clinical care and advancing research efforts.
Triomics has formed alliances with several prestigious cancer centers, including the likes of Memorial Sloan Kettering Cancer Center, MD Anderson, and Mount Sinai Tisch Cancer Center. Moreover, the company is collaborating with some of the largest community oncology practices in the United States, for instance, Texas Oncology. Through these partnerships, Triomics intends to tackle the pressing information burden that oncologists face, a challenge that existing systems struggle to manage.
"Oncology is experiencing an overwhelming amount of information that traditional systems were never equipped to handle, hindering the potential for better patient outcomes," explains Sarim Khan, Triomics’ co-founder and CEO. He stresses that clinicians, research coordinators, and medical assistants often grapple with a massive volume of records that have become too complex for manual processing. With Triomics, the goal is to transform this complexity into actionable intelligence embedded within the workflow specifically tailored for oncology.
Beyond simple data handling, Triomics has designed its platform to assist life sciences organizations with pivotal clinical-trial operations. The unique integration of deep provider workflows across cancer centers, coupled with specialized oncology AI infrastructure, aims to construct a robust foundation for future care and research applications.
The challenge faced in cancer care today is not the availability of information but the inefficient utilization of existing data. Patient histories often consist of extensive narratives, comprehensive clinical notes, and various reports and guidelines. The outcome is a labor-intensive process to make this information actionable. "To navigate through thousands of pages of notes and reports intelligently is no small feat," remarks Hrituraj Singh, co-founder and CTO of Triomics.
Triomics was established with the vision of utilizing AI agents to sift through longitudinal patient records, converting disorganized data into coherent, structured, and well-explained outputs. The platform then seamlessly integrates these insights into clinical and operational workflows. Unlike generic summarization tools, Triomics ensures that each output is sourced and verifiable, enriching the clinician’s workflow.
The application of the platform enables proactive clinical trial matching and efficient preparation for patient visits. The functionality also includes oncology data abstraction, ultimately benefiting registry and operational requirements. Data from users indicates remarkable outcomes—trial matches have increased by 40%, enrollments by over 30%, while chart review times were reduced by 67%. Furthermore, the platform has undergone peer-reviewed validation in prestigious journals like Nature Digital Medicine and has been showcased at significant conferences, highlighting the escalating demand for reliable AI capabilities in managing comprehensive patient records.
This evolution in oncology data management is already drawing attention. Dr. Lee Schwamm, the chief digital health officer at Yale New Haven Health System, expresses enthusiasm about partnering with Triomics for oncology clinical trial matching. He notes the time-consuming nature of registry abstraction and aims to automate this process to enhance efficiency and compliance with regulations.
Brandon Gleklen, a principal at Battery Ventures and the newest addition to Triomics' board, commends the groundwork laid by the company, remarking, "Triomics has created AI infrastructure that can function effectively with comprehensive patient data. The results at the leading cancer centers demonstrate tangible outcomes, including expedited enrollment processes and decreased chart review efforts. The unified AI infrastructure underlying these operations is rare for a company at this growth stage."
In summary, Triomics is on a transformative path to redefine clinical workflows in oncology through its cutting-edge AI platform. As they expand their funding and partnerships, the company's mission remains clear: to improve care processes and outcomes for cancer patients while pioneering the next generation of healthcare intelligence in oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.